Serum C-reactive protein concentrations in patients with pulmonary sarcoidosis

CHARLES R K HIND, KEVIN C FLINT, BARRY N HUDSPITH, DAVID FELMINGHAM, JONATHAN BROSTOFF, NORMAN McI JOHNSON

From the Departments of Medicine and Immunology, Middlesex Hospital, and the Department of Microbiology, University College Hospital, London

ABSTRACT In a prospective study serum C-reactive protein concentrations were measured in nine patients with “active” pulmonary sarcoidosis (as assessed by bronchoalveolar lavage lymphocyte counts, gallium-67 lung scanning, and serial pulmonary function testing), and in five patients with “inactive” disease. Active pulmonary sarcoidosis was associated either with no rise or with only a modest rise in serum C-reactive protein concentrations. In contrast, serum C-reactive protein concentrations in 12 patients with sputum positive pulmonary tuberculosis were considerably raised. Serum C-reactive protein may thus provide a valuable test in the differentiation of sarcoidosis from other conditions which it may mimic and which are known to induce an acute phase response.

Active pulmonary sarcoidosis is characterised by granuloma formation and an alveolitis arising primarily from activated T helper lymphocytes and mononuclear phagocytes. The mononuclear phagocytes are the building blocks of granulomas and are thought to have a central role in initiating and maintaining the T lymphocyte activation by secretion of the mediator interleukin-1 (IL-1). Consistent with this hypothesis is the finding that alveolar macrophages from patients with active pulmonary sarcoidosis release greater amounts of IL-1 than do those with inactive disease. This suggests that the degree of macrophage activation, and hence IL-1 production, may correlate with the activity of the lung disease.

Direct measurement of IL-1 is relatively recent and not well standardised. Indirect measurement, however, of circulating IL-1 levels is possible since this peptide plays a part in triggering the hepatic synthesis of several acute phase proteins, including the classical acute phase reactant C-reactive protein. Various techniques are now available for the precise and rapid estimation of the serum C-reactive protein concentration, and we have therefore investigated its possible role in monitoring disease activity in patients with pulmonary sarcoidosis.

Methods

Patients
We studied 14 patients (six male, eight female; mean age 42 years, range 19–59) with pulmonary sarcoidosis. There were five Caucasian, four West Indian and four Asian patients, and one Iranian. All had histologically proved sarcoidosis (11 cases) or a positive Kveim test, or both (10 cases). At the time of assessment of the activity of their pulmonary sarcoidosis, the mean duration of symptoms was 61 months (range 1–132), and only one patient was taking prednisolone. Two patients were at chest radiographic stage 0 (no apparent abnormality), four were at stage I (hilar adenopathy only), five were at stage II (hilar adenopathy and pulmonary infiltrates), and three were at stage III (pulmonary infiltrates only). Twelve patients also had extrathoracic disease (lymphadenopathy, three cases; skin, two cases; liver, two cases; uveitis, two cases; lymphadenopathy with episcleritis, splenomegaly, parotid enlargement, one case of each).

Assessment of disease activity
Patients were divided into two groups, according to the activity of the lung disease as assessed both by bronchoalveolar lavage cell counts and gallium-67 citrate scanning and by serial pulmonary function tests.
testing. Patients were considered to have “active” pulmonary sarcoidosis if more than 28% of their lavage cells were T lymphocytes and a gallium-67 lung scan was positive. Patients were classified as having “inactive” pulmonary sarcoidosis if 28% or less of their lavage cells were T lymphocytes and a gallium-67 scan was negative. In addition, standard pulmonary function tests were performed both before and at the time of the lavage and gallium scanning, and also repeated three and six months later.

**BLOOD INVESTIGATIONS**

Blood was taken for measurement of the serum C-reactive protein concentration at the time of the bronchoalveolar lavage, when the erythrocyte sedimentation rate (ESR) and serum angiotensin converting enzyme (SACE) concentration were also measured in some patients. Serum C-reactive protein was assayed by enzyme immunoassay (EMIT; Syva Co, Palo Alto, California). Intra-assay and interassay replicates gave results with a coefficient of variation of less than 10%. With this assay all 30 normal healthy people with a history of previous pulmonary tuberculosis had a serum C-reactive protein concentration of less than 10 mg/l (CRK Hind and D Felmingham, unpublished observations), which is the upper limit of the normal range as indicated by the assay’s manufacturers and also as reported by previous workers using radioimmunoassay techniques.

For comparison, blood was also taken for serum C-reactive protein measurement from 12 consecutive patients with sputum positive pulmonary tuberculosis before they started antituberculous chemotherapy. All these patients had pulmonary infiltrates or cavititation (or both) on their chest radiographs.

**STATISTICAL ANALYSIS**

Differences in results of the various objective measurements between groups of patients were sought by means of the Wilcoxon rank sum test.

**Results**

**DISEASE ACTIVITY**

Nine patients had “active” pulmonary sarcoidosis as defined above. In addition, in four of six patients a serial decrease in forced vital capacity (FVC) and transfer factor for carbon monoxide (TLco) was documented, and in all three patients subsequently treated with corticosteroids there was an increase in their FVC and TLco. SACE levels were raised in five of six patients, and the ESR in six of the tests (40 and 43 mm in the first hour: serum C-reactive protein concentration 0 and 24 mg/l respectively). None of these patients had biochemical evidence to suggest hepatic sarcoidosis.

Five patients had “inactive” pulmonary sarcoidosis and serial measurements of FVC in all five showed no change over six months. SACE concentrations were minimally raised in both patients tested (68 and 72 nmol/min/ml), and all four tested had a normal ESR. Both patients with histologically proved hepatic granulomas fell into this group.

**SERUM C-REACTIVE PROTEIN CONCENTRATION**

The serum C-reactive protein concentration was normal in seven of nine patients with “active” pulmonary sarcoidosis, and in all five patients in the “inactive” group (figure). The two patients with “active” pulmonary disease and a modestly raised serum C-reactive protein concentration (14 and 24 mg/l; ESR 15 and 43 mm in one hour respectively) both had anterior uveitis, a condition associated with an acute phase response in its own right.

In contrast, the serum C-reactive protein concentration was raised in all 12 patients with sputum positive pulmonary tuberculosis (mean 102, range 37–205 mg/l) (figure).

**Discussion**

Increased C-reactive protein production is a non-
specific response to most forms of tissue inflammation or damage. There are, however, several conditions in which, despite unequivocal evidence of active inflammation or tissue damage or both, there is only a minor increase in the serum C-reactive protein concentration, and in many cases it may even remain normal in the face of severe disease. These conditions include systemic lupus erythematosus, scleroderma, ulcerative colitis, and dermatomyositis. In contrast, intercurrent microbial infection does provoke a major C-reactive protein response in all these conditions.

The observations reported here would indicate that active pulmonary sarcoidosis should also be included in this group of conditions associated with minor or no increase in serum C-reactive protein concentration despite evidence of ongoing tissue inflammation (that is, alveolitis). The mechanisms for this apparently selective failure of the acute phase response of C-reactive protein are not known but, in view of the likely complexity of the pathways that mediate induction of the response, it is possible that some routes are inoperable. The inbred mouse strain NZB/W, which develops genetically determined autoimmune disease similar to lupus, behaves just like human patients with systemic lupus erythematosus with respect to its acute phase responses; and there may thus be a genetic basis for the phenomenon. In patients with pulmonary sarcoidosis this phenomenon may reflect the differences in immune responsiveness observed between the peripheral blood compartment and the lung. For example, while bronchoalveolar mononuclear cells have been reported to release increased amounts of interleukin-1, peripheral blood monocytes from patients with sarcoidosis release less IL-1 than do controls.

The other non-specific index of the presence of tissue inflammation is the erythrocyte sedimentation rate. Since this is largely determined by the concentration of proteins (for example, immunoglobulins) which do not reflect the intensity of the acute phase response, and hence IL-1 production, the aim of this study was not simply to compare serum C-reactive protein concentrations and erythrocyte sedimentation rates.

Whatever the mechanism for the absence of a strong C-reactive protein response in active pulmonary sarcoidosis, this difference in the behaviour of C-reactive protein may help to distinguish pulmonary sarcoidosis from conditions which it may mimic and which are known to induce an acute phase response—for example, pulmonary tuberculosis.

We thank Syva Company for kindly providing the serum C-reactive protein assay kits.

References
6 Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarco-
11 International Committee for Standardisation in Hae-
motology. Reference method for the erythrocyte sedi-
m entation rate (ESR) test on human blood. *Br J Haemato-
13 Shine B, De Beer FC, Pepys MB. Solid phase radio-
immunoassay for human C reactive protein. *Clin Chir-
18 Whicher JT, Martin MFR, Dieppe PA. Absence of prosta-
Serum C-reactive protein concentrations in patients with pulmonary sarcoidosis


